However, we found no association between this subpopulation and any of the well-established risk factors for chemoresistance after conventional intensive chemotherapy (i.e., secondary AML, karyotype, FLT3-ITD, NPM1 mutations, CD34 expression) or long-term AML-free survival. Here, FLT3 is linked to acute myeloid leukemia.